Navigation Links
Study compares standard against newer treatment in women whose breast cancer has spread
Date:12/7/2012

(Lebanon, NH, 12/7/12) Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by Peter A. Kaufman, M.D., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

"We didn't show a statistically significant superiority of eribulin over capecitabine, which was our goal," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H. "However, eribulin demonstrated a trend favoring an overall survival benefit, in comparison to capecitabine, which is a widely accepted and used standard therapy in this setting. Additionally, this is the first study demonstrating that eribulin is active earlier in the course of metastatic breast cancer," Kaufman said.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy treatment regimens for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues examined whether eribulin would be effective as an earlier-line treatment in women with metastatic breast cancer. They randomly assigned 1,102 patients to eribulin or capecitabine. Patients had all received prior anthracycline- and taxane-based therapy and received the study drug as the first, second or third line of therapy for metastatic disease.

The median overall survival for patients treated with eribulin was 15.9 months compared with 14.5 months for patients treated with
'/>"/>

Contact: Donna M. Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
(Date:5/18/2013)... Just a few extra cups of coffee each month ... disease known as primary sclerosing cholangitis (PSC), a new ... Rochester, Minn., found that drinking coffee was associated with ... lead to cirrhosis of the liver, liver failure and ... cause-and-effect relationship. "While rare, PSC has extremely ...
(Date:5/18/2013)... ROCHESTER, Minn. -- Regular consumption of coffee is ... cholangitis (PSC), an autoimmune liver disease, Mayo Clinic ... the Digestive Disease Week 2013 conference in Orlando, ... of the bile ducts that results in inflammation ... of the liver, liver failure and biliary cancer. ...
(Date:5/18/2013)... Park City, Utah (PRWEB) May 18, 2013 ... new information on insurance agents’ role in ... flexible alternatives to traditional employer sponsored health benefits, ... defined contribution and health reimbursement arrangements ... Department of Health and Human Services (HHS) recently ...
(Date:5/18/2013)... 18, 2013 The “World Healthcare IT ... studies the major market drivers, restraints, and opportunities in ... , Browse , 89 market ... TOC on "Healthcare IT Market" , ... on reports. , The global healthcare IT market is ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... might play a part , , MONDAY, April 6 (HealthDay News) -- ... jar -- in other words, those who have more difficulty delaying ... older. , The same seems true of young children ... It,s unclear whether these findings, from two studies published in the ...
... credit unions raised $1 million for children,s hospitals nationwide, including ... associated with the Credit Union Cherry Blossom Ten Mile Run. ... ... last year, credit unions raised $1 million for children,s hospitals ...
... surgeon on the medical staff of THE HEART HOSPITAL ... for Baylor Health Care System, has been named president-elect ... Mack will provide leadership for the more than 5,600 ... members of the Society."Dr. Mack is an outstanding surgeon ...
... N.C. New research at Wake Forest University School ... of drugs used to prevent bone fractures in osteoporosis ... study,s findings appear in the current issue of ... of Pharmacovigilance covering the safe and proper use of ...
... Contact in TreatmentCOLUMBIA, S.C., April 6 ... Silver Honors for Health Plans and Health Networks by ... . The honor was announced at the ... Protection Awards Gala on April 1-2 in ...
... Health and Wellness through Education and Research InitiativesNEW ... joined forces as a leadership contributor with the ... Alliance. The partnership,s aim is to ensure the ... new racetrack accreditation program are addressed in a ...
Cached Medicine News:Health News:Kids Who Lack Self-Control May Be Prone to Weight Gain 2Health News:Kids Who Lack Self-Control May Be Prone to Weight Gain 3Health News:Credit Union Cherry Blossom Ten Mile Run Cherry Blossom Ten-Miler Raises $400,000 For Children's National Medical Center 2Health News:Surgeon Named President-Elect of National Organization 2Health News:Surgeon Named President-Elect of National Organization 3Health News:Link between widely used osteoporosis drugs and heart problems probed 2Health News:Link between widely used osteoporosis drugs and heart problems probed 3Health News:Companion Benefit Alternatives Awarded Silver Honors for Best Practices in Health Plans and Health Networks by URAC 2Health News:Companion Benefit Alternatives Awarded Silver Honors for Best Practices in Health Plans and Health Networks by URAC 3Health News:Pfizer Animal Health Becomes Leadership Contributor to the NTRA Safety and Integrity Alliance 2Health News:Pfizer Animal Health Becomes Leadership Contributor to the NTRA Safety and Integrity Alliance 3
(Date:5/17/2013)... PARIS , May 17, 2013  Sanofi (EURONEXT: ... the pivotal study, JAKARTA , examining ... its primary endpoint in both dose groups. The primary ... of spleen volume. Consistent with data reported in previous ... nausea and vomiting. Full results will be presented at ...
(Date:5/16/2013)... SINGAPORE and ZURICH , May ... Agency for Science, Technology and Research (A*STAR) and ... the first healthy volunteer has been dosed in a Phase ... on Cytos, proprietary bacteriophage Qbeta virus-like particle (VLP) technology. In ... of this novel vaccine candidate and its potential to protect ...
(Date:5/16/2013)... -- Today, the National Patient Advocate Foundation acknowledges that the ... recently approved a bill that would prohibit insurers who ... fees for newer, more expensive oral anti-cancer drugs than ... side-effects. However, the bill was amended to include a ... be a barrier to patients with cancer and in ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... 7, 2011 The U.S. Food and Drug Administration ... treat patients with late-stage (metastatic) head and neck cancer. ... Combined with chemotherapy, Erbitux extended the lives of ... chemotherapy alone. Erbitux already is FDA-approved for certain types ...
... Psychemedics Corporation, hair testing for drugs of ... announced today that its laboratory has received international ... of laboratory testing including drugs of abuse ... The International Organization for Standardization/International Electrotechnical Commission ...
Cached Medicine Technology:FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 2FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 3Psychemedics Awarded ISO/IEC 17025 International Accreditation 2Psychemedics Awarded ISO/IEC 17025 International Accreditation 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Plastic Citrate Tube, .109M / 3.2%...
Medicine Products: